BioXcel Therapeutics Inc expected to post a loss of $6.38 a share - Earnings Preview

BioXcel Therapeutics

07/03/2025 12:45

BioXcel Therapeutics Inc BTAI.OQ BTAI.O is expected to show a rise in quarterly revenue when it reports  results on March 10 (estimated) for the period ending December 31 2024

The New Haven Connecticut-based  company is expected to report a 87.9% increase in revenue to $706.67 thousand from $376 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for BioXcel Therapeutics Inc is for a loss of $6.38 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $32.00​, above​ its last closing price of $2.74. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-8.00
-8.67
-5.12
Beat
40.9
Jun. 30 2024
-11.12
-11.36
-3.36
Beat
70.4
Mar. 31 2024
-10.25
-11.17
-13.92
Missed
-24.6​
Dec. 31 2023
-15.12
-14.56
-12.16
Beat
16.5
​​Sep. 30 2023
-21.50
-20.86
-27.52
Missed
-31.9
Jun. 30 2023
-28.83
-28.01
-29.28
Missed
-4.5​
Mar. 31 2023
-28.96
-25.89
-29.44
Missed
-13.7
Dec. 31 2022
-23.92
-23.14
-31.20
Missed
-34.8

This summary was machine generated March 7 at 12:45 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)